9,11-diflouro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one | 207391-14-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 羽扇豆生物碱
• 英文名称: 9,11-diflouro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one
• 英文别名: 3,5-Difluoro-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
• CAS: 207391-14-8
• 化学式: C₁₁H₁₂F₂N₂O
• 分子量: 226.226
• InChiKey: CDSOWLPTABQYKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Pfizer Inc.

  公开号：US20030134844A1

  公开（公告）日：2003-07-17

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  这项发明涉及尼古丁型乙酰胆碱受体激动剂用于治疗不安腿综合征（RLS）。该发明还涉及尼古丁型乙酰胆碱受体激动剂在制造治疗RLS药物中的应用。本发明还涉及一种含有尼古丁型乙酰胆碱受体激动剂的治疗RLS的药物组合物。
• Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
  申请人：——

  公开号：US20030065173A1

  公开（公告）日：2003-04-03

  Pyridone-fused azabicyclic compounds of the formula 1 and their pharmaceutically acceptable salts and prodrugs, wherein R 1 , R 2 and R 3 are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula I in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, Huntington's Chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia , analgesia, attention deficit disorder (ADD), multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), anxiety, obesity, Tourette's Syndrome and ulcerative colitis.

  公式1中的吡啶并咪唑化合物及其药学上可接受的盐和前药，其中R1、R2和R3的定义如下，以及它们的中间体和制备方法。公式I化合物在治疗与胆碱能功能降低有关的神经和精神障碍方面的组合物和方法，例如尼古丁成瘾、亨廷顿舞蹈病、迟发性运动障碍、多动症、躁狂症、阅读障碍、精神分裂症、镇痛、注意力缺陷障碍（ADD）、多发性梗塞性痴呆、与胆碱能功能降低有关的神经和精神障碍、阿尔茨海默病、帕金森病、注意力缺陷过动症（ADHD）、焦虑症、肥胖症、抽动症和溃疡性结肠炎的治疗中使用。
• Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Saltarelli D. Mario

  公开号：US20050250806A1

  公开（公告）日：2005-11-10

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  本发明涉及使用烟碱乙酰胆碱受体激动剂治疗不宁腿综合征（RLS）。本发明还涉及使用烟碱乙酰胆碱受体激动剂制造治疗 RLS 的药物。本发明还涉及一种含有烟碱乙酰胆碱受体激动剂的治疗 RLS 的药物组合物。
• PYRIDONE-FUSED AZABICYCLIC- OR CYTISINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN ADDICTION THERAPY
  申请人：PFIZER INC.

  公开号：EP0937077A1

  公开（公告）日：1999-08-25
• NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME
  申请人：Pfizer Products Inc.

  公开号：EP1439836A1

  公开（公告）日：2004-07-28